| 제2형 당뇨병 약제치료 지침 2017 개정안: Glucagon-Like Peptide-1 수용체작용제 |
|
김현진 |
|
|
| Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association. |
|
Hyun Jin Kim |
|
Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea. kimhj43@cnuh.co.kr |
|
|
| Abstract |
|
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy, which was a change from the previous guideline that recommended them only as a combination therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) have demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RAs may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA. |
| Key Words:
Cardiovascular diseases, Diabetes mellitus, Glucagon-like peptide-1 receptor agonist, Hypoglycemia, Obesity, Practice guideline |
|
PDF Links
Full text via DOI
Download Citation
